Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.85% | -7.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.85% | -7.86% | |||
| Cost of Revenue | 8.74% | -10.39% | |||
| Gross Profit | 12.01% | -6.41% | |||
| SG&A Expenses | -8.73% | 9.41% | |||
| Depreciation & Amortization | -0.04% | 1.83% | |||
| Other Operating Expenses | 106.97% | -162.45% | |||
| Total Operating Expenses | 4.32% | -18.19% | |||
| Operating Income | 60.28% | 1,934.12% | |||
| Income Before Tax | 248.13% | -506.61% | |||
| Income Tax Expenses | 761.85% | -263.45% | |||
| Earnings from Continuing Operations | 227.19% | -532.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 33.34% | -24.01% | |||
| Net Income | 227.09% | -533.93% | |||
| EBIT | 60.28% | 1,934.12% | |||
| EBITDA | 75.37% | 14.96% | |||
| EPS Basic | 228.46% | -534.96% | |||
| Normalized Basic EPS | 62.93% | 399.65% | |||
| EPS Diluted | 226.54% | -534.96% | |||
| Normalized Diluted EPS | 60.50% | 399.65% | |||
| Average Basic Shares Outstanding | -1.07% | -0.21% | |||
| Average Diluted Shares Outstanding | 0.42% | -0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 13.39% | -1.02% | |||